Form 4 for CLDX Celldex Therapeutics, Inc.

Accepted 2021-12-28 00:00:00 ET · period of report 2021-12-23 · accession 0001179110-21-011251 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DM	2021-12-28	2021-12-23	CLDX	Martin Samuel Bates	SVP, CFO	M - OptEx	$5.68	+7,000	33.9K	+26%	+$39.7K
D	2021-12-28	2021-12-23	CLDX	Martin Samuel Bates	SVP, CFO	S - Sale+OE	$42.00	-9,500	24.4K	-28%	-$399.0K
DM	2021-12-28	2021-12-23	CLDX	Martin Samuel Bates	SVP, CFO	M - OptEx	$0.00	-7,000	24.4K	-22%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-12-23	M	A	3,250	$9.02	30,128	D	—	—
2	Common	Common Stock	2021-12-23	S	D	9,500	$42.00	24,378	D	—	—	(F1) The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.
3	Common	Common Stock	2021-12-23	M	A	3,750	$2.78	33,878	D	—	—
4	Derivative	Incentive Stock Option (Right to Buy)	2021-12-23	M	D	3,250	$0.00	9,530	D	$9.02 · — to 2028-06-13	3,250 Common Stock	(F2) 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
5	Derivative	Incentive Stock Option (Right to Buy)	2021-12-23	M	D	3,750	$0.00	24,421	D	$2.78 · — to 2029-06-19	3,750 Common Stock	(F3) 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.